Plus Therapeutics Soars 25.71% on FDA Trial Approval

Plus Therapeutics' stock surged 25.71% in pre-market trading on June 26, 2025, driven by significant developments in the company's pipeline.

The surge in Plus Therapeutics' stock price can be attributed to the FDA's green light for the company to initiate trials for its brain cancer drug. This approval has sparked investor enthusiasm, as FDA clearances are often seen as a major catalyst for small-cap biotech stocks.

Additionally, the company's stock has seen impressive gains following the FDA's clearance for a pediatric brain cancer trial. This trial, valued at $3 million, brings hope for new treatment options in the fight against childhood brain cancer.

Plus Therapeutics has also announced a comprehensive restructuring of its $15 million March 2025 equity financing. This move is aimed at strengthening the company's financial position and accelerating its development programs.